MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517063850 A) filed by Pramand Llc, Bedford, U.S.A., on July 4, for 'chemical tissue ablation with hydrogel matrix and corresponding medical applications.'
Inventor(s) include Andrews, Payton; and Bassett, Michael.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "Compositions, methods, and applications for ablative-chemical infused hydrogels are described. The hydrogels are biodegradable and can be formed in situ. The hydrogels are effective for delivering tissue ablative chemicals to target sites. The hydrogel delivered tissue ablative chemicals can be particularly effective for performing intrauterine ablation, even when fibroids are present, or for scarring fallopian tubes for birth control via minimally invasive procedures. The hydrogels can also be particularly effective at avoiding contact of tissue ablative chemicals with off-target tissues. The hydrogels can be installed using various delivery vehicles, including injections and catheters. The hydrogels can be designed to be retained in the target site for a period of hours to days, so that targeted tissue ablation can proceed in an ambulatory patient. Methods for transcervical installation of in situ formed hydrogels into the uterus or one or more fallopian tubes are described."
The patent application was internationally filed on Dec. 01, 2023, under International application No.PCT/US2023/082149.
Disclaimer: Curated by HT Syndication.
